Safety and efficacy of a feed additive consisting of l‐leucine produced with Corynebacterium glutamicum KCCM 80421 for all animal species (CJ Europe GmbH) Authors: EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Roberto Edoardo Villa, Giovanna Azimonti, Eleftherios Bonos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Ronette Gehring, Boet Glandorf, Maryline Kouba, Marta López‐Alonso, Francesca Marcon, Giovanna Martelli, Carlo Nebbia, Alena Pechová, Miguel Prieto‐Maradona, Katerina Theodoridou, Paul Brantom, Luca Tosti, Montserrat Anguita, Matteo L. Innocenti, Maria Kolona, Fabiola Pizzo, Jordi Tarrés‐Call Published: 2026 ABSTRACT AbstractFollowing a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of l‐leucine produced with a genetically modified strain of Corynebacterium glutamicum (KCCM 80421) when used as nutritional (amino acid) and/or sensory (flavouring compound) feed additive in feed and water for drinking for all animal species and categories. The l‐leucine manufactured by fermentation with C. glutamicum KCCM 80421 did not give rise to any safety concern regarding the genetic modifications of the production strain. No viable cells nor DNA of the production strain were detected in the final product. The use of l‐leucine produced with C. glutamicum KCCM 80421 in feed was considered safe for the target species when used as amino acid to supplement in appropriate amounts the diet, according to the nutritional needs of the target species; or when used as a flavouring compound. The FEEDAP Panel had concerns on the use of l‐leucine in water for drinking. The use of l‐leucine produced by fermentation with C. glutamicum KCCM 80421 in animal nutrition as amino acid or a flavouring compound was considered safe for the consumers of products from animals receiving the additive and for the environment. Regarding the user safety, the additive was not considered irritant to skin or eyes and was not considered a potential skin sensitiser. The additive was regarded as an effective source of the amino acid l‐leucine for all non‐ruminant species. To be as efficacious in ruminants as in non‐ruminants, it should be protected from ruminal degradation. l‐Leucine was considered efficacious when used as a flavouring compound in animal nutrition. INTRODUCTION Background and Terms of Reference Regulation (EC) No 1831/2003 1 establishes the rules governing the Community authorisation of additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any person seeking authorisation for a feed additive or for a new use of feed additive shall submit an application in accordance with Article 7. The European Commission received a request from CJ Europe GmbH 2 for the authorisation of the additive consisting of l‐leucine produced with Corynebacterium glutamicum KCCM 80421, when used as a feed additive for all animal species (category: nutritional additives; functional group: amino acids, their salts and analogues; category: sensory additives; functional group: flavouring compounds). According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application to the European Food Safety Authority (EFSA) as an application under Article 4(1) (authorisation of a feed additive or new use of a feed additive). The dossier was received on 10 December 2024 and the general information and supporting documentation are available at https://open.efsa.europa.eu/questions/EFSA‐Q‐2024‐00696. The particulars and documents in support of the application were considered valid by EFSA as of 14 April 2025. According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and documents submitted by the applicant, shall undertake an assessment in order to determine whether the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety for the target animals, consumer, user and the environment and on the efficacy of the feed additive consisting of l‐leucine produced with C. glutamicum KCCM 80421, when used under the proposed conditions of use (see Section 3.1.4 ). Additional information The additive l‐leucine produced with C. glutamicum KCCM 80421 has not been previously authorised as a feed additive in the European Union. l‐Leucine produced by fermentation using different production strains is currently authorised for its use in all animal species as a nutritional and sensory additive. 3 The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) issued a series of scientific opinions on the safety and efficacy of l‐leucine produced by fermentation using different production strains, when used as a nutritional additive and as sensory additive. 4 DATA AND METHODOLOGIES Data The present assessment is based on data submitted by the applicant in the form of a technical dossier 5 in support of the authorisation request for the use of l‐leucine produced with C. glutamicum KCCM 80421 as a feed additive. In accordance with Article 38 of the Regulation (EC) No 178/2002 6 and taking into account the protection of confidential information and of personal data in accordance with Articles 39 to 39e of the same Regulation, and of the Decision of EFSA's Executive Director laying down practical arrangements concerning transparency and confidentiality, 7 a non‐confidential version of the dossier has been published on Open.EFSA. According to Article 32c(2) of Regulation (EC) No 178/2002 and to the Decision of EFSA's Executive Director laying down the practical arrangements on pre‐submission phase and public consultations, EFSA carried out a public consultation on the non‐confidential version of the technical dossier from 9 July to 30 July 2025 for which no comments were received. The confidential version of the technical dossier was subject to a target consultation of the interested Member States from 16 April 2025 to 16 July 2025 for which the received comments were considered for the assessment. The FEEDAP Panel used the data provided by the applicant together with data from other sources, such as previous risk assessments by EFSA or other expert bodies, peer‐reviewed scientific papers and other scientific reports, to deliver the present output. EFSA has verified the European Union Reference Laboratory (EURL) report as it relates to the methods used for the control of the l‐leucine in animal feed. 8 Methodologies The approach followed by the FEEDAP Panel to assess the safety and the efficacy of l‐leucine is in line with the principles laid down in Regulation (EC) No 429/2008 9 and the relevant guidance documents: Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP Panel, 2017a), Guidance on the identity, characterisation and conditions of use of feed additives (EFSA FEEDAP Panel, 2017b), Guidance on the assessment of the safety of feed additives for the target species (EFSA FEEDAP Panel, 2017c), Guidance on the characterisation of microorganisms used as feed additives or as production organisms (EFSA FEEDAP Panel, 2018), Guidance on the assessment of the safety of feed additives for the environment (EFSA FEEDAP Panel, 2019), Guidance on the assessment of the safety of feed additives for the users (EFSA FEEDAP Panel, 2023), Guidance on the assessment of the efficacy of feed additives (EFSA FEEDAP Panel, 2024) and EFSA statement on the requirements for whole genome sequence analysis of microorganisms intentionally used in the food chain (EFSA, 2024). ASSESSMENT l‐Leucine (≥ 90% l‐leucine on a dry matter [DM] basis) produced by fermentation with a genetically modified strain of C. glutamicum (KCCM 80421) is intended to be used as nutritional additive (functional group: amino acids, their salts and analogues) and as sensory additive (functional group: flavouring compounds) in feed and water for drinking for all animal species and categories. Characterisation Characterisation of the production organism l‐Leucine is produced with a genetically modified strain of C. glutamicum, which is deposited in the Korean Culture Center of Microorganisms (KCCM) with accession number KCCM 80421. 10 The taxonomic identification of the production strain KCCM 80421 was confirmed ■■■■■ based on the whole genome sequence (WGS) data. 11 ■■■■■. ■■■■■ The antimicrobial susceptibility of the production strain was tested ■■■■■ against the battery of antibiotics recommended by the FEEDAP Panel (EFSA FEEDAP Panel, 2018). 12 ■■■■■ Therefore, the production strain is considered susceptible to all relevant antibiotics. The interrogation of the WGS data for the presence of antimicrobial resistance (AMR) genes was done against ■■■■■. 13 ■■■■■ Therefore, the FEEDAP Panel concludes that the strain harbours no acquired AMR genes and raises no safety concerns. Characterisation of the parental or recipient microorganism and genetic modification description, The parental strain is ■■■■■. 14 The purpose of the genetic modification was to increase the production of l‐leucine. 15 ■■■■■ to obtain the production strain under assessment: ■■■■■■■■■■■■■■■■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ 16 ■■■■■. Manufacturing process l‐Leucine is produced by fermentation with the genetically modified strain C. glutamicum KCCM 80421 as production strain. 17 ■■■■■ 18 ■■■■■. The applicant stated that no antimicrobial substances are used in the manufacturing process. 19 Characterisation of the additive l‐Leucine (International Union of Pure and Applied Chemistry (IUPAC) name: 2‐amino‐4‐methylpentanoic acid), a compound identified by Chemical Abstracts Service (CAS) No 61‐90‐5 and European Inventory of Existing Commercial Chemical Substances (EINECS) No 200‐522‐0, has a molecular weight of 131.17 g/mol; the molecular formula is C6H13NO2 and its structural formula is given in Figure 1. Structural formula of l‐leucine. The additive is specified by the applicant to contain ≥ 90% l‐leucine on dry matter (DM) basis, ≤ 2% other amino acids on DM and ≤ 3% water. 20 The data provided by the applicant on the batch‐to‐batch variation 21 of the additive are reported in Table 1. Other data on impurities, 22 physico‐chemical and technological properties 23 of the additive are reported in Appendix A. TABLE 1Data on the batch‐to‐batch variation of the additive under assessment. The data presented are average values and (range). The number of batches analysed per parameter, or group of parameters are indicated in []. Specifications l‐Leucine (% DM)≥ 90Other amino acids (% DM)≤ 2Water (%)≤ 3 Batch‐to‐batch variation [5] l‐Leucine (% DM) 1 92.4 (91.4–93.4)Other amino acids (% DM)0.9Tyrosine (%)0.57 (0.56–0.60)Methionine (%)0.32 (0.30–0.33)Valine (%)< 0.050–0.051Rest of amino acids (%) 2 < LOQWater (%)1.6 (1.2–2.8) Physical form SolidAbbreviations: DM, dry matter; LOQ, limit of quantification. 1 Analytical method to determine l‐leucine is Commission Regulation (EC) No 152/2009, III, F. 2 The corresponding limits of quantification for the other amino acids analysed are: 0.01 for tryptophan; 0.05 for lysine, cystine, asparagine acid, threonine, serine, glutamic acid, proline, glycine, alanine, phenylalanine, histidine, arginine; 0.10 for isoleucine. Data on the batch‐to‐batch variation of the additive under assessment. The data presented are average values and (range). The number of batches analysed per parameter, or group of parameters are indicated in []. Abbreviations: DM, dry matter; LOQ, limit of quantification. Analytical method to determine l‐leucine is Commission Regulation (EC) No 152/2009, III, F. The corresponding limits of quantification for the other amino acids analysed are: 0.01 for tryptophan; 0.05 for lysine, cystine, asparagine acid, threonine, serine, glutamic acid, proline, glycine, alanine, phenylalanine, histidine, arginine; 0.10 for isoleucine. The data on batch‐to‐batch variation provided by the applicant showed compliance with the specifications. The total amount of identified material on a DM basis was 98.2%. The chiral purity of l‐leucine was analysed and the l‐enantiomer confirmed. 24 The FEEDAP Panel considers that the microbial contamination and the amounts of the detected impurities do not raise safety concerns. This includes also the residues of the ■■■■■, for which, taking into account its nature (and amount present in the additive), a separate assessment is done in Appendix B. The presence of viable cells of the production strain was investigated ■■■■■. 25 ■■■■■. No viable cells of the production strain were found in any of the test samples. The presence of DNA from the production strain was analysed ■■■■■. 26 ■■■■■. No DNA from the production strain was detected in any of the samples. Conditions of use l‐Leucine is intended to be used in feed for all animal species. It can be added via premixture or directly into feed (including complete feed and complementary feed), or to water for drinking, without maximum or minimum levels and without withdrawal period. No inclusion levels have been proposed, when used as nutritional additive, as the quantitative requirements of l‐leucine, in quantitative terms, depend on the nutrient composition, in particular the amino acid composition of the unsupplemented diet, the species, the age of the animal, the physiological state of the animal, the performance level and the environmental conditions. When used as feed flavouring, l‐leucine is proposed to be used at a maximum recommended level of inclusion of 25 mg/kg feed. 27 Safety Safety of the production microorganism The parental strain is considered to be safe. The genetic modifications performed to obtain the production strain C. glutaminum KCCM 80421 have the purpose to increase the production of l‐leucine. The production strain belongs to a species, C. glutamicum, that is included in the qualified presumption of safety (QPS) list when used for production purposes (EFSA BIOHAZ Panel, 2023b). The taxonomic identification of the production strain was unequivocally established, it does not carry acquired AMR genes and the genetic modification does not raise safety concerns. No viable cells nor DNA of the production strain were detected in the final product. Therefore, the FEEDAP Panel concludes that the additive does not pose any safety concern regarding the production strain. Safety for the target species, consumers and the environment The l‐leucine requirements of the target animal species and the safety of this essential amino acid in non‐ruminant and ruminant nutrition are well known by feed formulators and available in general publications on animal nutrition. The additive is produced by fermentation with a genetically modified C. glutamicum KCCM 80421, and no safety concerns were identified for the production strain (see Section 3.2.1), the fermentation process and its residues/metabolites. Moreover, the resulting product is highly purified (≥ 90% l‐leucine and up to 1.8% of unidentified material observed in batch analysis on a dry matter basis). Concerns on the use of the additive would not derive from the l‐leucine, which is considered safe but may arise from residues of the fermentation process/production strain remaining in the final product. l‐Leucine produced with C. glutamicum KCCM 80421, is safe for the target species when used to supplement the diet in appropriate amounts to satisfy the animal requirements. However, the FEEDAP Panel reiterates its statement on the safety of the use of amino acids in water for drinking (EFSA FEEDAP Panel, 2010), for hygienic reasons and for the risk of nutritional imbalances when amino acids are administered simultaneously in feed and in water for drinking. Since the levels proposed for the use of l‐leucine as flavouring compound (25 mg/kg complete feed) are substantially lower than the animal requirements as nutrient, the FEEDAP Panel considers that l‐leucine produced by fermentation with C. glutamicum KCCM 80421 is safe for the target species when used as a flavouring compound. The absorption and metabolic fate of l‐leucine in the animals is well known. The amino acid l‐leucine, supplemented to feed, will be incorporated into proteins of tissues and/or products of animal origin and any of its potential excess will be metabolised and excreted. Therefore, the protein composition of tissues and products of animal origin will not be affected using l‐leucine in animal nutrition. Therefore, the Panel considers that the use of the additive in animal nutrition is safe for the consumer. Neither the C. glutamicum KCCM 80421, nor its recombinant DNA were detected in the final product. The final product does not pose any environmental safety concern associated with the genetic modification. The amino acid l‐leucine is a physiological and natural component of animals and plants. It is not excreted unchanged, but it is metabolised with its degradation products excreted as urea/uric acid and carbon dioxide. The use of the product l‐leucine in animal nutrition would not lead to any localised increase in the concentration in the environment. The use of the additive in water for drinking, when given in addition to complete diets with a well‐balanced amino acid profile, would disturb the nitrogen balance and increase nitrogen excretion via urine. The Panel concludes that the use of l‐leucine produced by fermentation with C. glutamicum KCCM 80421 in animal nutrition is safe for the environment. The safety of ■■■■■ is described in Appendix B. The FEEDAP Panel concludes that the use of ■■■■■ in the manufacturing of the additive, at the proposed used levels, is considered safe for the target species, consumers and the environment. Safety for the user Based on the highest dusting potential measured value (see Section 3.1.2), the FEEDAP Panel considers that the exposure of users through inhalation is likely. An acute inhalation study was performed following the OECD Testing Guideline (TG) 433. 28 The lethal concentration 50 (LC50) is more than 5 mg/L. The skin irritation potential of l‐leucine was tested in a study performed according to the OECD TG 439, which showed that l‐leucine is not a skin irritant (UN GHS ‘No Category’). 29 The eye irritation potential of l‐leucine was tested in a study performed according to OECD TG 492B, which showed that the l‐leucine is not an eye irritant (UN‐GHS ‘No Category’). 30 The skin sensitisation potential of l‐leucine was tested in series of studies performed according to OECD TGs 442C, 442E and 429. 31 , 32 , 33 Although some equivocal results were obtained in the in vitro studies, the outcome of the in vivo study indicated that l‐leucine is not a skin sensitiser. Conclusions on safety for the user Based on the information available, the additive is not irritant to skin or eyes and is not a skin sensitiser. Efficacy Efficacy studies are not required for amino acids that occur naturally in plant and animal proteins. The nutritional role of the amino acid l‐leucine is well established in the scientific literature. The additive l‐leucine is regarded as an efficacious source of the essential amino acid l‐leucine for non‐ruminant nutrition. For the supplemental l‐leucine to be as efficacious in ruminants as in non‐ruminant species, it would require protection against degradation in the rumen. As l‐leucine is used in food as flavouring compound, it is expected that it can provide a similar function in feed and no further demonstration of efficacy is necessary. Post‐market monitoring The FEEDAP Panel considers that there is no need for specific requirements for a post‐market monitoring plan other than those established in the Feed Hygiene Regulation 34 and Good Manufacturing Practice. CONCLUSIONS The production strain C. glutamicum KCCM 80421 does not raise safety concerns regarding the genetic modifications. No viable cells nor DNA of the production strain are detected in the final product. Therefore, the FEEDAP Panel concludes that the additive does not pose any safety concern regarding the production strain. The use of l‐leucine produced by fermentation with C. glutamicum KCCM 80421 in feed as nutritional additive or as flavouring compound is safe for the target species. The FEEDAP Panel has concerns about the use of l‐leucine in water for drinking. The use of l‐leucine produced by fermentation with C. glutamicum KCCM 80421 in animal nutrition is considered safe for consumers and for the environment. Regarding user safety, l‐leucine produced with C. glutamicum KCCM 80421 is not irritant to skin or eyes and is not a skin sensitiser. The feed additive consisting of l‐leucine produced by fermentation with C. glutamicum KCCM 80421 is regarded as an effective source of the amino acid l‐leucine for all non‐ruminant species. In order to be as efficacious in ruminants as in non‐ruminants, it should be protected from ruminal degradation. l‐Leucine is considered efficacious when used as a flavouring compound in animal nutrition. ABBREVIATIONS antimicrobial resistance average nucleotide identity Chemical Abstracts Service colony forming unit Chinese hamster lung cell line cytochalasin B dry matter European Inventory of Existing Chemical Substances ethylene oxide European Union Reference Laboratory EFSA Scientific Panel on Additives and Products or Substances used in Animal Feed gel permeation chromatography International Union of Pure and Applied Chemistry Korean Culture Center of Microorganisms limit of detection limit of quantification non‐dioxin‐like PCBs Organisation for Economic Co‐operation and Development polychlorinated biphenyls polychlorinated dibenzo‐p‐dioxins polychlorinated dibenzofurans propylene oxide qualified presumption of safety replicative population doubling room temperature toxic equivalent factors for dioxins, furans and dioxin‐like PCBs whole genome sequence World Health Organization REQUESTOR European Commission QUESTION NUMBER EFSA‐Q‐2024‐00696 COPYRIGHT FOR NON‐EFSA CONTENT EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source. PANEL MEMBERS Roberto Edoardo Villa, Giovanna Azimonti, Eleftherios Bonos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Ronette Gehring, Boet Glandorf, Maryline Kouba, Marta López‐Alonso, Francesca Marcon, Giovanna Martelli, Carlo Nebbia, Alena Pechová, Miguel Prieto‐Maradona and Katerina Theodoridou. LEGAL NOTICE The published scientific output includes information items that have been redacted, in accordance with the confidentiality requests submitted by the applicant, pending a decision thereon by EFSA. Redactions may be subject to review once a decision on such confidentiality requests is taken by EFSA.